Suzhou Ribo Life Science Co., Ltd. Class H (6938) Receives a Buy from CICCTip Ranks·Sep 3 at 04:05 AM06938-14.08%
From Biotech Breakthroughs to Consumer Shifts: Resurgence Signals in HK StocksGlobal Report·Sep 1 at 11:33 AM02632-18.59%06938-14.08%
Earnings Divergence: H&H Group Profits Surge While Aviation and Pharma Lag in Mid-2026Global Report·Sep 1 at 09:17 AM02605-0.43%02357+0.17%
Weekly Recap | RIBOLIFE-B +0.65%, first-half swing to profitWeekly Review·Aug 29 at 04:52 AM06938-14.08%
Suzhou Ribo Life Science swings to FY26 H1 profit of RMB 23.45 million; revenue rises to RMB 419.74 millionPUBT·Aug 27 at 11:14 AM06938-14.08%MDGL-0.28%
Suzhou Ribo Life Science board meets to review interim results, consider dividendPUBT·Aug 17 at 08:45 AM06938-14.08%
The Limits of Capital Aggregation: Structural Discounts in the Uncategorized Tail of Hong Kong StocksGlobal Report·Aug 13 at 09:44 AM01978-0.45%06938-14.08%
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH ExpansionSimplywall·Aug 9 at 11:38 AMMDGL-0.28%06938-14.08%
Suzhou Ribo wins EMA approval for Phase 2b vortosiran trial in stroke prevention for atrial fibrillationPUBT·Jul 28 at 11:58 AM06938-14.08%
Ribo reports vortosiran Phase IIa trial results for coronary artery diseaseWorldPharmaceuticals·Jul 23 at 11:38 AM06938-14.08%
10:11 ETRibo revela datos positivos del ensayo de fase 2a de vortosiranprnewswire·Jul 22 at 02:13 PM06938-14.08%
Suzhou Ribo Reports First Global Proof-of-Concept for siRNA FXI Therapy in CADTip Ranks·Jul 22 at 08:40 AM06938-14.08%
